Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

iBio Inc

IBIO ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.47

▲ +3.52%

Market Cap $73.03M · Vol 99.21K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$73.03M

Micro Cap

Div Yield

N/A

EPS Growth

+80.49%

YoY

RSI (14)

58.97

Momentum

Beta

1.31

vs Market

52W High

$3.82

61.52% below

52W Low

$0.76

93.42% above

Volume

99.21K

Avg 130.98K

P/B

0.99

Price-to-book

ROE

N/A

Return on equity

Free Float

94.35%

Public shares

Shariah Compliance8 STANDARDS

✗ iBio Inc (IBIO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IBIO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.38%

+2.80%

-20.11%

-48.78%

YTD

-23.83%

+73.80%

-78.07%

-99.77%

Financials & Valuation

TTM · Annual

Total Revenue	$400.00K
Net Income	$-18,377,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-4,650.50%
Net Profit Margin	-4,594.25%
ROE	N/A
ROA · ROIC	-70.79% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	20.03
P/B	0.99
P/FCF	N/A
EPS Growth	+80.49%
Outstanding Shares	49.68M

Technical Indicators

50-Day SMA	$1.50
200-Day SMA	$1.84
RSI (14)	58.97
Beta	1.31
52-Week High	$3.82
52-Week Low	$0.76

Volume Today	99.21K
Avg Daily Volume (30D)	130.98K
Relative Volume	0.76x
Volatility (10D)	38.58
Volatility (30D)	41.02
Free Float	94.35%

Analyst Consensus

BUY

Current Price $1.47

Mean Target $5.53

52W Low$0.76 52W High$3.82

Current

Target

$0.76 $3.82

Current Analyst target

+275.85% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001T0R8W3

ISINUS4510337086

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateSep 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.02% ONC BeOne Medicines AG +1.18% RVMD Revolution Medicines Inc -0.09% 068270.KS Celltrion Inc -2.27% ABVX Abivax SA +1.53%

Company Profile

iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.